0001493152-23-016388.txt : 20230511 0001493152-23-016388.hdr.sgml : 20230511 20230511161037 ACCESSION NUMBER: 0001493152-23-016388 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 23911090 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000876343 false 0000876343 2023-05-11 2023-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 11, 2023

 

Lineage Cell Therapeutics, Inc.

(Exact name of registrant as specified in charter)

 

California   001-12830   94-3127919

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2173 Salk Avenue, Suite 200

Carlsbad, California

   92008
(Address of principal executive offices)   (Zip Code)

 

(442) 287-8990

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common shares   LCTX   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 11, 2023, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2023, a copy of which is furnished as Exhibit 99.1.

 

The information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release issued May 11, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lineage Cell Therapeutics, Inc.
     
Date: May 11, 2023 By: /s/ George A. Samuel III
  Name: George A. Samuel III
  Title: General Counsel and Corporate Secretary

 

-3-

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

 

●Additional RG6501 (OpRegen®) Phase 1/2a Clinical Study Results Presented at ARVO 2023
●Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group
●Awarded CIRM Grant to Support 1st Annual Spinal Cord Injury Investor Symposium
●Signed Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune iPSC Lines
●Initiated Preclinical Testing of ANP1 for Treatment of Hearing Loss

 

CARLSBAD, CA – May 11, 2023 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

 

“During the first quarter of this year, the Lineage team executed on multiple fronts, advancing our clinical and preclinical cell transplant programs while continuing support of our existing alliances and establishing new ones,” stated Brian M. Culley, Lineage CEO. “A key area of focus was our partnership with Roche and Genentech and supporting the ongoing Phase 2a clinical study of OpRegen in patients with GA secondary to AMD, which is enrolling and treating patients at multiple sites in the U.S. Through presentations at various medical and scientific conferences, we also broadened our efforts to enhance awareness of OpRegen’s potential to provide durable anatomical and functional improvements in dry AMD patients. In addition, we established new collaborations with CIRM and the Christopher & Dana Reeve Foundation to support a new SCI conference which aims to identify, discuss, and address gaps in the product development process and elevate the patient’s voice in the treatment process. Looking ahead, we will be working on regulatory interactions for OPC1 while continuing to maintain our commitment to disciplined spending and making responsible investments in disease settings where we believe the use of differentiated cell transplants can provide a meaningful impact for patients.”

 

Recent milestones and activities included:

 

-RG6501 (OpRegen)

 

○Continued execution under our collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing Phase 2a multi-center clinical study in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD):

 

■Additional sites expected to come online this year.

 

○Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:

 

■Preliminary evidence of durable anatomical and functional improvements following administration of OpRegen cells was presented at 2023 Association for Research in Vision and Ophthalmology Annual Meeting and other medical and scientific meetings.

 

-Received CIRM grant to support 1st Annual Spinal Cord Injury Investor Symposium

 

○California Institute for Regenerative Medicine (CIRM) awarded Lineage an educational grant with a total award value of $50,000, recognizing this event as an important mission-specific conference, which will allow for the exchange of scientific information, create opportunities to accelerate the development of stem cell therapies to patients, increase the likelihood of successful treatments reaching patients, addresses an unmet clinical need, and can be impactful to CIRM’s overall mission.

 

 

 

 

  - Strengthened OPC1 intellectual property portfolio

 

○United States Patent and Trademark Office has granted a patent for the Company’s U.S. patent application No. 16/750,975, now U.S. Patent No. 11,603,518, entitled “Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells,” with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury. The patent has a term that would expire no earlier than 2040.

 

-Executed option and license agreement with Eterna Therapeutics

 

○Enables development of novel beta 2 microglobulin (B2M)-deficient iPSC lines, which Lineage will evaluate for development into differentiated cell transplant therapies, specifically for the treatment of certain central nervous system disorders and other neurology indications.

 

-Initiated preclinical testing of ANP1

 

○Preclinical testing underway through a collaboration with the University of Michigan and Yehoash Raphael, Ph.D., The R. Jamison and Betty Williams Professor of Otolaryngology, Department of Otolaryngology-Head and Neck Surgery and Lab Director at the University of Michigan Kresge Hearing Research Institute.

 

Some of the events anticipated by Lineage include:

 

  - Type B Meeting with FDA to discuss a proposed amendment to the Investigational New Drug Application (IND) for OPC1 to enable clinical testing of a novel spinal cord delivery system.
  - Amendment of an IND for OPC1 to enable clinical testing of a novel spinal cord delivery system.
  - Submission of an additional OPC1 manuscript describing magnetic resonance imaging (MRI) findings from the subacute studies in both thoracic and cervical spinal cord injury.
  - Updates from ongoing ANP1 preclinical testing at the University of Michigan Kresge Hearing Research Institute under a collaboration with the University of Michigan.

 

Balance Sheet Highlights

 

Cash, cash equivalents, and marketable securities totaled $46.8 million as of March 31, 2023, which is expected to support planned operations into Q3 2024.

 

First Quarter Operating Results

 

Revenues: Lineage’s revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended March 31, 2023 were approximately $2.4 million, a net decrease of $2.8 million as compared to $5.2 million for the same period in 2022. The decrease was driven by less collaboration and licensing revenue recognized from deferred revenues from the Roche Agreement.

 

Operating Expenses: Operating expenses are comprised of research and development (“R&D”) expenses and general and administrative (“G&A”) expenses. Total operating expenses for the three months ended March 31, 2023 were $8.9 million, a decrease of $2.5 million as compared to $11.4 million for the same period in 2022.

 

R&D Expenses: R&D expenses for the three months ended March 31, 2023 were $4.2 million, a net increase of $1.2 million as compared to $3.0 million for the same period in 2022. The net increase was primarily driven by $0.5 million for nonclinical-related expenses to support the OPC1 program, and $0.2 million in OpRegen program expenses to support the Roche collaboration. Another $0.4 million and $0.2 million of the increase was related to R&D spending on the new auditory neuron and photoreceptor cell therapy programs, respectively.

 

G&A Expenses: G&A expenses for the three months ended March 31, 2023 were $4.7 million, a net decrease of $3.7 million as compared to approximately $8.4 million for the same period in 2022. The decrease was primarily driven by $3.5 million in lower litigation and legal expenses, mostly due to the Asterias litigation settlement expense accrued in the prior year, and $0.2 million in lower expense for accounting and tax services.

 

Loss from Operations: Loss from operations for the three months ended March 31, 2023 was $6.6 million, an increase of $0.2 million as compared to $6.4 million for the same period in 2022.

 

 

 

 

Other Income/(Expenses), Net: Other income (expenses), net for the three months ended March 31, 2023 reflected other income, net of $0.4 million, compared to other expense, net of ($0.7) million for the same period in 2022. The net income was primarily driven by fair market value changes in marketable equity securities, interest income from our marketable debt securities, and other income recorded in the current period related to the employee retention credit program, partially offset by exchange rate fluctuations related to Lineage’s international subsidiaries.

 

Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended March 31, 2023 was $4.4 million, or $0.03 per share (basic and diluted), compared to a net loss attributable to Lineage of $7.1 million, or $0.04 per share (basic and diluted), for the same period in 2022.

 

Conference Call and Webcast

 

Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 18, 2023, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 8339383.

 

About Lineage Cell Therapeutics, Inc.

 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

 

 

 

 

Forward-Looking Statements

 

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the significance of the Phase 2a clinical study of OpRegen; that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the third quarter of 2024; the timing and nature of events and milestones anticipated to occur in 2023, including plans and expectations regarding publications and presentations related to our programs, the timing of anticipated regulatory submissions to the FDA related to our programs, the potential future achievements of our clinical, preclinical and development programs, the initiation of clinical trials and the availability of clinical data updates related to our programs; plans and expectations regarding existing collaborations, including our plans to develop new cell lines into differentiated cell transplant therapies and potential product candidates, and the potential indications thereof as a result of the Agreement with Eterna; our ability to broaden awareness of our mission, programs and accomplishments; and the potential of our cell therapy platform and our ability to provide an meaningful impact for patients. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to use our cash, cash equivalents and marketable securities more quickly than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that OpRegen may never be proven to provide durable anatomical functional improvements in dry-AMD patients, that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that the planned regulatory interaction with FDA for OPC1 may not enable further clinical development; that the SCIIS will not accelerate SCI research, clinical trials or product development; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Lineage Cell Therapeutics, Inc. IR

 

Ioana C. Hone

(ir@lineagecell.com)

(442) 287-8963

 

LifeSci Advisors

 

Daniel Ferry

(daniel@lifesciadvisors.com)

(617) 430-7576

 

Russo Partners – Media Relations

 

Nic Johnson or David Schull

(Nic.johnson@russopartnersllc.com)

(David.schull@russopartnersllc.com)

(212) 845-4242

 

Tables to follow

 

 

 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

 

  

March 31, 2023

(Unaudited)

  

December 31,

2022

 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $15,451   $11,355 
Marketable securities   31,363    46,520 
Accounts receivable, net   203    297 
Prepaid expenses and other current assets   2,638    1,828 
Total current assets   49,655    60,000 
           
NONCURRENT ASSETS          
Property and equipment, net   5,584    5,673 
Deposits and other long-term assets   635    627 
Goodwill   10,672    10,672 
Intangible assets, net   46,659    46,692 
TOTAL ASSETS  $113,205   $123,664 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable and accrued liabilities  $5,252   $8,608 
Lease liabilities, current portion   912    916 
Financing lease, current portion   51    36 
Deferred revenues   11,009    9,421 
Other current liabilities   1    - 
Total current liabilities   17,225    18,981 
           
LONG-TERM LIABILITIES          
Deferred tax liability   273    2,076 
Deferred revenues, net of current portion   24,017    27,725 
Lease liability, net of current portion   2,542    2,860 
Financing lease, net of current portion   133    84 
Other long-term liabilities   -    2 
TOTAL LIABILITIES   44,190    51,728 
           
SHAREHOLDERS’ EQUITY          
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2023 and December 31, 2022   -    - 
Common shares, no par value, 250,000 shares authorized; 170,174 and 170,093 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively   441,299    440,280 
Accumulated other comprehensive loss   (3,107)   (3,571)
Accumulated deficit   (367,742)   (363,370)
Lineage Cell Therapeutics, Inc. shareholders’ equity   70,450    73,339 
Noncontrolling deficit   (1,435)   (1,403)
Total shareholders’ equity   69,015    71,936 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $113,205   $123,664 

 

 

 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

  

Three Months Ended

March 31,

 
   2023   2022 
REVENUES:        
Collaboration revenues  $2,121   $4,865 
Royalties   265    372 
Total revenues   2,386    5,237 
           
Cost of sales   (119)   (176)
           
Gross profit   2,267    5,061 
           
OPERATING EXPENSES:          
Research and development   4,185    2,988 
General and administrative   4,724    8,469 
Total operating expenses   8,909    11,457 
Loss from operations   (6,642)   (6,396)
OTHER INCOME (EXPENSES):          
Interest income, net   410    1 
Unrealized gain (loss) on marketable equity securities   40    (735)
Gain on revaluation of warrant liability   1    221 
Other expenses, net   (16)   (184)
Total other income (expenses), net   435    (697)
LOSS BEFORE INCOME TAXES   (6,207)   (7,093)
           
Deferred income tax benefit   1,803    - 
           
NET LOSS   (4,404)   (7,093)
           
Net loss attributable to noncontrolling interest   32    6 
           
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.  $(4,372)  $(7,087)
           
NET LOSS PER COMMON SHARE:          
BASIC  $(0.03)  $(0.04)
DILUTED  $(0.03)  $(0.04)
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:          
BASIC   170,127    169,647 
DILUTED   170,127    169,647 

 

 

 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

 

  

Three Months Ended

March 31,

 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss attributable to Lineage Cell Therapeutics, Inc.  $(4,372)  $(7,087)
Net loss attributable to noncontrolling interest   (32)   (6)
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash (used in) provided by operating activities:          
Accretion of income on marketable debt securities   (326)   - 
Unrealized (gain)/loss on marketable equity securities   (40)   735 
Depreciation expense, including amortization of leasehold improvements   138    150 
Amortization of intangible assets   33    28 
Stock-based compensation   1,031    1,106 
Deferred income tax benefit   (1,803)   - 
Gain on revaluation of warrant liability   (1)   (221)
Foreign currency remeasurement   466    75 
Changes in operating assets and liabilities:          
Accounts receivable, net   95    50,321 
Prepaid expenses and other current assets   (847)   573 
Accounts payable and accrued liabilities   (3,463)   (18,905)
Deferred revenue and other liabilities   (2,121)   (4,865)
Net cash (used in) provided by operating activities   (11,242)   21,904 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of marketable debt securities   (7,718)   - 
Maturities of marketable debt securities   23,332    - 
Purchase of equipment and other assets, net   (188)   (46)
Net cash provided by (used in) investing activities   15,426    (46)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from employee options exercised   51    379 
Common shares received and retired for employee taxes paid   (37)   (8)
Proceeds from exercise of subsidiary warrants, net   -    2 
Proceeds from sale of common shares   -    148 
Repayment of financing lease liability   (13)   (8)
Net cash provided by financing activities   1    513 
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (100)   (42)
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   4,085    22,329 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
At beginning of the period   11,936    56,277 
At end of the period  $16,021   $78,606 
SUPPLEMENTAL DISCLOSURES          
Cash paid for interest  $2   $5 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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lctx-20230511.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 lctx-20230511_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 lctx-20230511_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2023
Entity File Number 001-12830
Entity Registrant Name Lineage Cell Therapeutics, Inc.
Entity Central Index Key 0000876343
Entity Tax Identification Number 94-3127919
Entity Incorporation, State or Country Code CA
Entity Address, Address Line One 2173 Salk Avenue
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code (442)
Local Phone Number 287-8990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol LCTX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000876343 2023-05-11 2023-05-11 iso4217:USD shares iso4217:USD shares 0000876343 false 8-K 2023-05-11 Lineage Cell Therapeutics, Inc. CA 001-12830 94-3127919 2173 Salk Avenue Suite 200 Carlsbad CA 92008 (442) 287-8990 false false false false Common shares LCTX NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lineagecell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm lctx-20230511.xsd lctx-20230511_lab.xml lctx-20230511_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "lctx-20230511_lab.xml" ] }, "presentationLink": { "local": [ "lctx-20230511_pre.xml" ] }, "schema": { "local": [ "lctx-20230511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "LCTX", "nsuri": "http://lineagecell.com/20230511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-11to2023-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://lineagecell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-11to2023-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-016388-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-016388-xbrl.zip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